Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rank sum test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Rank sum test. Displaying page 1 of 1.
    EudraCT Number: 2016-001193-15 Sponsor Protocol Number: FASTERCC-001 Start Date*: 2016-07-06
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II ...
    Medical condition: Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to TKI and mTOR inhibitor treatment of metastatic renal cell carcinoma patients. The present trial will assess...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10064282 Vaginal mucositis LLT
    20.0 100000004856 10028130 Mucositis oral LLT
    20.0 100000004856 10065721 Anal mucositis LLT
    20.0 100000004867 10028127 Mucositis LLT
    20.0 100000004855 10065881 Pharyngeal mucositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004187-32 Sponsor Protocol Number: AVT-01/2/AST/02 Start Date*: 2007-01-23
    Sponsor Name:Avontec GmbH
    Full Title: Efficacy and safety of AVT-01 5 mg once daily over 7 days in patients with moderate persistent atopic asthma – A double-blind, randomized, placebo-controlled clinical study
    Medical condition: Male outpatients aged 18 - 65 with moderate persistent atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004190-94 Sponsor Protocol Number: AVT-01/2/AST/03 Start Date*: 2007-01-23
    Sponsor Name:Avontec GmbH
    Full Title: Efficacy and safety of AVT-01 10 mg once daily over 7 days in patients with moderate persistent atopic asthma – A double-blind, randomized, placebo-controlled clinical study
    Medical condition: Male outpatients aged 18 - 65 with moderate persistent atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002769-44 Sponsor Protocol Number: ESAP Start Date*: 2015-09-28
    Sponsor Name:Medical University of Graz
    Full Title: Efficacy and safety of an accelerated outpatient protocol for hymenoptera venom immunotherapy
    Medical condition: Immunotherapy against systemic anaphylactic sting reactions
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10001749 Allergy to sting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002944-10 Sponsor Protocol Number: c16174 Start Date*: 2019-02-27
    Sponsor Name:Memorial Sloan Kettering Cancer Center
    Full Title: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Medical condition: Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000281-37 Sponsor Protocol Number: EBS-101-CL-001 Start Date*: 2020-05-07
    Sponsor Name:Emalex Biosciences, Inc.
    Full Title: A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette...
    Medical condition: Children and Adolescent Subjects with Tourette’s Syndrome grater than or equal to 6 and less than 18 years of age.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000266-11 Sponsor Protocol Number: 2012-772 Start Date*: 2014-05-27
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.
    Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery.
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002547-29 Sponsor Protocol Number: ATB-203 Start Date*: 2019-11-21
    Sponsor Name:Atox Bio
    Full Title: Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with ...
    Medical condition: Acute kidney injury due to intra-abdominal infection/sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10080269 Stage 2 acute kidney injury LLT
    20.1 100000004857 10080271 Stage 3 acute kidney injury LLT
    20.1 100000004862 10079983 Complicated intra-abdominal infection LLT
    20.0 100000004862 10040050 Sepsis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000302-12 Sponsor Protocol Number: BUC-CLIN-303 Start Date*: 2016-07-13
    Sponsor Name:ARCA biopharma, Inc.
    Full Title: GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) PL (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021871-10 Sponsor Protocol Number: IC-01-01-05-004 Start Date*: 2012-04-18
    Sponsor Name:Innovacell Biotechnologie AG - Life Science Center Innsbruck
    Full Title: A multicenter, randomized, double-blinded, parallel-group, placebocontrolled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urin...
    Medical condition: Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005315-18 Sponsor Protocol Number: HMX3501 Start Date*: 2009-07-21
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A confirmatory, placebo-controlled, randomised, double-blind, single-dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal hydromorphone – naloxone ratio w...
    Medical condition: Moderate to severe chronic non-cancer or cancer pain with opioid induced constipation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10033371 Pain PT
    14.0 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) GB (Completed) FR (Completed) NL (Completed) DE (Completed) AT (Completed) BE (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-005049-11 Sponsor Protocol Number: AAA-III-01 Start Date*: 2012-04-25
    Sponsor Name:Advanced Accelerator Applications
    Full Title: A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperabl...
    Medical condition: Patients with inoperable, progressive, OctreoScan® positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours), who are treated with 20 mg or 30 mg Octreotide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062392 Carcinoid tumor of the small bowel LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) PT (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 12:09:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA